LUNG DISEASES, INTERSTITIAL

This large, completed Phase 3 trial tested whether a new oral medicine called BI 1015550 could help adults with progressive fibrosing interstitial lung diseases (PF-ILDs). Over 1,100 participants were randomly assigned to take either one of two doses of the medicine or a placebo …

This study tested the long-term safety of nintedanib, a medication that slows lung scarring, in children and adolescents with progressive interstitial lung disease. Participants aged 6-17 took nintedanib capsules twice daily for at least 3 years while researchers monitored for si…

This study aimed to create and test a screening tool that uses common risk factors to identify which rheumatoid arthritis patients should get a special lung scan. Researchers enrolled over 1,300 patients with rheumatoid arthritis who had at least two risk factors for lung disease…

This study aimed to monitor the safety of the drug Ofev in real-world patients in Japan with a specific type of progressive, scarring lung disease. It tracked 425 patients who were newly prescribed Ofev to see what side effects, especially liver problems, they experienced. The go…

This study tested whether using portable oxygen therapy helps people with chronic lung disease walk farther during a 6-minute walking test. Researchers compared how far 40 participants could walk while breathing normal air versus while using their prescribed nasal oxygen. The goa…

This study aimed to understand if changes in a standard lung function test (FVC) over one year of treatment with the drug nintedanib are related to changes in patients' reported cough and shortness of breath. It observed 158 adults with progressive, scarring lung diseases (exclud…